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The antigenic component of a common Lyme disease vaccine is
recombinant outer surface protein A (rOspA) of Borrelia burgdor-
feri (Bb), the causative agent of Lyme disease. Coincidentally,
patients with chronic, treatment-resistant Lyme arthritis develop
an immune response against OspA, whereas those with acute
Lyme disease usually do not. Treatment-resistant Lyme arthritis
occurs in a subset of Lyme arthritis patients and is linked to
HLA.DRB1*0401 (DR4) and related alleles. Recent work from our
laboratory identified T cell crossreactivity between epitopes
of OspA and lymphocyte function-associated antigen 1L chain
(LFA-1L) in these patients. We generated a form of rOspA,
FTK-OspA, in which the LFA-1LrOspA crossreactive T cell epitope
was mutated to reduce the possible risk of autoimmunity in
genetically susceptible individuals. FTK-OspA did not stimulate
human or mouse DR4-restricted, WT-OspA-specific T cells, whereas
it did stimulate antibody responses specific for WT-OspA that were
similar to mice vaccinated WT-OspA. We show here that the
protective efficacy of FTK-OspA is indistinguishable from that of
WT-OspA in vaccination trials, as both C3HHeJ and BALBc FTK-
OspA-vaccinated mice were protected from Bb infection. These
data demonstrate that this rOspA-derived vaccine lacking the
predicted cross-reactive T cell epitope, but retaining the capacity to
elicit antibodies against infection, is effective in generating pro-
tective immunity.
Lyme disease is the most common vector-borne disease in theUnited States, with 15,000 new cases each year (1). It is
caused by the spirochete Borrelia burgdorferi sensu stricto (Bb),
which is transmitted through the bite of infected ticks of the
Ixodes family, primarily Ixodes scapularis in the Eastern and
North central United States (2). Early symptoms of Lyme
disease are nonspecific and can include malaise, fever, and chills.
Because these symptoms are not specific to Lyme disease alone,
combined with the fact that patients often do not recall being
bitten (3), individuals may experience debilitating late manifes-
tations of untreated Lyme disease weeks to months later,
including musculoskeletal, cardiologic, and neurologic dysfunc-
tions before diagnosis (4–6). Prevention is the best method for
avoiding infection and subsequent disease-related complica-
tions. However, personal protective strategies have not always
proven to be successful (7, 8), indicating a need for an efficacious
vaccine.
Lyme disease vaccine development has primarily targeted the
outer surface protein A (OspA) of Bb (9). This surface-
expressed lipoprotein is significantly up-regulated in the tick
midgut, and anti-OspA antibodies can passively protect mice
against Bb infection (10). OspA-based vaccines function by
killing the bacteria in the tick midgut, thereby blocking trans-
mission of Bb to the human host (11, 12). The first Food and
Drug Administration-approved form of the vaccine, LYMErix
(GlaxoSmithKline, Research Triangle Park, NC), consisted of a
lipidated recombinant OspA (rOspA) from Bb strain ZS7 ad-
sorbed with aluminum hydroxide adjuvant. Clinical trials in
adults showed a 76% efficacy in preventing symptomatic Lyme
disease after three doses (13). In children, vaccination efficacy
has been shown to be close to 100% (14, 15). A nonadjuvant,
lipidated form of rOspA Lyme vaccine, ImuLyme [Pasteur
Merieux Connaught USA, Swiftwater, PA (16)], was found
to have 92% efficacy after three injections. Thus, vaccination
with rOspA is an effective preventative measure against Lyme
disease.
A consequence of disseminated Bb infection in up to 10% of
infected individuals is a condition described as treatment-
resistant Lyme arthritis (TRLA) (17). Arthritis persists in TLRA
patients after long-term antibiotic therapy, suggesting that bac-
terial persistence is not necessary (18). Notably, in these patients,
serum IgG reactivity to OspA correlates with the onset of
prolonged episodes of arthritis (19). The incidence of TRLA has
been correlated with the rheumatoid arthritis-associated MHC
class II alleles, which include HLA-DRB1*0401 (DR4) (20). Our
laboratory identified human lymphocyte function-associated anti-
gen (hLFA)-1L326–345 as a possible autoantigen in the context of
DR4, based on sequence similarity to a region of OspA spanning
amino acid residues 165–173 (OspA165–173) (21). By using an MHC
class II DR4 tetramer specific for OspA164–176, we isolated T cells
that were also hLFA-1L326–345-reactive from the synovial f luid
of DR4 homozygous patients with TRLA (22). These findings
suggested that the pathogenesis of TRLA may be due to an
autoimmune response triggered by OspAhLFA-1L crossreac-
tivity. The observed T cell crossreaction between hLFA-1L
chain and OspA raised the concern that rOspA-based vaccines
may trigger autoimmunity in susceptible individuals.
In this study, we report the generation of an rOspA vaccine,
FTK-OspA, in which the putative cross-reactive T cell epitope,
Bb OspA165–173, has been altered to resemble the corresponding
peptide sequence of Borrelia afzelii. Human and mouse T cells
specific for Bb OspA165–173 did not respond to FTK-OspA,
whereas FTK-OspA was as effective as WT-OspA in generating
protective antibody responses against Bb infection in both C3H
HeJ and BALBc mice.
Materials and Methods
Mice. Six- to 8-week-old female C3HHeJ and BALBc mice
were obtained from The Jackson Laboratory. HLA-DR4-IE
chimeric transgenic mice (23) were a gift from T. Forsthuber
(Case Western Reserve University, Cleveland) and were bred in
our facility. All animal use protocols are approved by the
accredited animal care and use committees at Tufts University
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and Texas A&M University Health Science Center Institute of
Biosciences and Technology, respectively.
Bb. Low-passage Bb N40 or B31 were cultured in complete
Barbour–Stoenner–Kelly (BSK) medium (Sigma) at 34°C and
counted under darkfield microscopy.
Recombinant OspA Mutagenesis and Protein Production. OspA was
amplified from a plasmid containing the OspA sequence from
Bb strain B31 by using published primers (24). The 5 leader
sequence and lipidation site were omitted as described (25), and
the resulting truncated product was cloned into the pGEX4T.1
GST-fusion expression vector (Amersham Biosciences, Piscat-
away, NJ).
Site-directed mutagenesis was performed in two separate
rounds by using the QuikChange PCR mutagenesis kit (Strat-
agene). First round primers: P6K-Fwd gctatgttcttgaaggaAAGct-
Tactgctgaaaaaacaacattgg (HindIII); and second round primers
P1FP2T-Fwd gaggttttaaaaggcTTCACGcttgaaggaaagcttac.
Uppercase letters indicate substituted bases and underlined
letters correspond to a restriction endonuclease site that was
added. Recombinant FTK-OspA protein and empty vector
control lysate (EV-Ctrl) were produced in Escherichia coli BL-21
and purified by using GST-Sepharose 4B bead slurry (Amer-
sham Biosciences). Cleavage with thrombin released the rOspA
proteins of 28 kDa from the beads and the GST moieties.
Antibody Assays. WT-OspA, FTK-OspA, or EV-Ctrl lysate were
plated at 100 ng per well in 50 l of 0.1 M NaHCO3, pH 8.2
overnight at 4°C. Plates were blocked with 1% BSA0.5% Tween
200.02% sodium azidePBS, pH 7.4 for 2 h at room tempera-
ture, or overnight at 4°C. Two-fold serial dilutions of mAb LA-2
or H5332 (26, 27) were plated at 100 l per well and incubated
at room temperature for 2.5 h. Antibody binding was detected
with Zymax alkaline phosphatase-labeled goat anti-mouse IgG
(Zymed), diluted 1:5,000 in 100 l per well and allowed to bind
for 1 h at 21°C. Plates were developed with 100 l per well
p-nitrophenyl phosphate (Pierce Biotechnology, Rockford, IL)
substrate in diethanolamine buffer. Reactions were stopped with
50 l per well 2M NaOH. Data are expressed as OD405 with the
background values subtracted.
LA-2-containing hybridoma supernatant (a generous gift of
M. Simon, Max-Planck-Institut fur Immunobiologie, Freiburg,
Germany) was purified by using HiTrap rProtein A column
(Amersham Biosciences) for use in equivalency assays. The
resulting antibody was biotin labeled with the mini-biotin-X-X
protein labeling kit (Molecular Probes). mAbs were quantified
by using both the BCA protein estimation kit (Pierce Biotech-
nology) and UV absorbance.
LA-2 equivalency describes the ability of serum antibodies to
bind to and block the mAb LA-2 by competitive ELISA (26, 28,
29). In this assay, WT-OspA was bound to plates at 500 ngml
in 100 l of 0.1 M NaHCO3, pH 8.2 overnight at 4°C. Serial
twofold dilutions of mouse sera were plated in triplicate over-
night at 4°C; serial twofold dilutions of unlabeled LA-2 (starting
at 1 gml) were placed on each plate as a standard curve. Plates
were washed and biotinylated LA-2 was plated at 300 ngml for
30 min at room temperature. Each plate contained positive and
negative control pooled sera samples. Plates were washed, and
NeutrAvidin-alkaline phosphatase conjugate (Pierce Biotech-
nology) was added at 0.1 gml in 100 l for at least 30 min at
room temperature. Plates were developed with p-nitrophenyl
phosphate substrate.
OspA ImmunizationVaccination and Bb infection. Six- to 8-week-old
Female C3HHeJ and BALBc mice were immunized s.c. with
100 l of containing adjuvant plus WT-OspA, FTK-OspA,
EV-Ctrl, or adjuvant alone. Primary immunizations were pre-
pared in complete Freund’s adjuvant (CFA), whereas subse-
quent immunizations were made by using incomplete Freund’s
adjuvant (30). C3HHeJ mice were immunized on days 0, 14, and
28 with 10 g of each protein or EV-Ctrl. Two weeks after the
last immunization, mice were infected with 104 Bb N40 (passage
2) in the right hind footpad. BALBc mice were immunized with
20 g of each protein or EV-Ctrl on days 0 and 28, and were
infected with 104 Bb B31 (passage 2) in 100 l through intra-
dermal injection at the base of the tail 2 weeks after the last
immunization (31). Mock-infected controls were injected with
100 l of BSK media and were not immunized with OspA.
Over the course of three weeks after Bb infection, ankle
swelling was monitored by means of caliper measurements of the
anterior-posterior tibiotarsal joint thickness. Mice were killed on
the fourth week after infection. Bb in the blood or bladder of
C3HHeJ mice were detected by culturing two drops of asep-
tically harvested blood or whole bladders in 1.5 ml of complete
BSK medium (Sigma) at 34°C for 2 weeks and then examining
culture supernatant by darkfield microscopy. In experiments
using BALBc mice, vaccine efficacy was determined by har-
vesting and culturing the blood and tissues (ear, heart, bladder,
and joints) 7 and 14 days post infection, respectively. Briefly,
50 l of blood or tissue samples were cultured in 6 ml of BSK
for 2 weeks at 34°C in a CO2-enriched atmosphere by using a
GasPak chamber (Becton Dickinson and Company, Franklin
Lakes, NJ) and were assessed for the presence of Bb by darkfield
microscopy (30).
DNA Isolation and PCR. Genomic DNA extractions were per-
formed on ear tissues harvested from infected C3HHeJ mice by
using a protocol adapted from Morrison et al. (32). Briefly, ear
tissue was digested at 37°C for 2–4 h in 300 l of 0.1%
collagenase A in PBS, pH 7.4, then were digested overnight at
55°C after adding 300 l of 0.2 mg/ml proteinase K200 mM
NaCl20 mM TrisHCl50 mM EDTA1% SDS. Extraction,
ethanol precipitation, and resuspension were followed by diges-
tion with RNase A, and an additional extraction and ethanol
precipitation with a final resuspension in 10 mM TrisHCl, pH
8.5. Primers used for amplification of Bb recA and murine
nidogen DNA were as published (32). PCR was performed by
using 200, 20, and 2 ng of DNA, 0.5 M recA primers, or 0.05 M
nidogen primers, and 27 l of Platinum Taq Supermix (Invitro-
gen) in a final volume under the following conditions: at 95°C,
5 min to denature, followed by 33 cycles of 95°C for 15 sec, 60°C
for 30 sec, and 69°C for 30 sec. Products were visualized on
ethidium bromide-stained agarose gels.
Murine T Cell Hybridomas (THys). OspA-specific DR4 (DR4–51 and
DR4–38) and DR1 (L3C4)-restricted THy were generated as
described (22, 33). For stimulation studies, 3 104 THy cells per
well were cultured for 48 h in complete RPMI medium 1640
10% FCS with an equal number of antigen-presenting cells
(APCs): DAP-DR4 and DAP-DR1 for DR4-and DR1-restricted
hybridomas, respectively. Culture supernatants were harvested
and relative quantities of IL-2 secretions were determined by
sandwich ELISA using standard protocols (BD Pharmingen).
Recombinant mouse IL-2 standards were used to determine the
linear range of the assay.
Testing of Human T Cell Clones. T cells were isolated and cloned
from synovial f luid of a DR4 homozygous patient as described
(22, 33). For proliferation assays, autologous Epstein–Barr virus-
transformed B cells were treated with mitomycin C (Sigma) for
use as APCs. APCs and T cell clones were added at 2 104 cells
with antigen as indicated. At 48 h, 100 l of the medium was
removed for cytokine analysis, and plates were pulsed with 0.5
Ci (1 Ci  37 GBq) of 3H-labeled thymidine for 18 h. Plates
were counted on a -plate scintillation counter (Perkin–Elmer,
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Boston). Data are expressed as  cpm, which is the mean cpm
of wells with antigen minus the mean cpm of wells with medium
alone. Cytokine analysis by using sandwich ELISAs were per-
formed as described (33). Values were determined by comparing
OD450 values to the standard curve generated for each plate.
Serum OspA-Specific Antibody Response. WT-OspA was plated at 1
gml in 50 l of 0.1 M NaHCO3, pH 8.2 and were allowed to
bind overnight at 4°C. Plates were blocked with 200 l of 1%
BSA0.5% Tween 200.02% sodium azidePBS, pH 7.4 for 2 h
at 21°C. Threefold serial dilutions of preinfection-immunized
mouse sera were plated at room temperature for 2 h. Alkaline
phosphatase-coupled detecting antibodies were plated at 100 l
per well for 1 h. Total IgG was detected with Zymax goat
anti-mouse IgG (Zymed) at 1:2,000; isotype-specific detection
antibodies were used at 1:500 (clonotyping system, Southern
Biotechnology Associates). Plates were developed with p-
nitrophenyl phosphate as described above. Data are expressed as
OD405 with the plate background values subtracted.
Results
Generation of rOspA. The immunodominant DR4-restricted T cell
epitope of Bb OspA, OspA165–173, is located in the thirteenth
-pleat of the central -sheet structure (34). We designed a
modification of this epitope to prevent its association with DR4
and thereby inhibit the activation of T cells specific for this
region, by using a DR-binding algorithm (35). FTK-OspA was
generated by making the substitutions Y165 to F, V166 to T, and
T170 to K in WT-Bb OspA, thus resembling the peptide se-
quence found in B. afzelii (36), a Borrelia strain not associated
with chronic arthritis (Fig. 1a). The DR4-binding algorithm
predicted that the MHC-binding score would drop from6.5 for
WT-OspA, and to 0.2 in the FTK-OspA mutant (Fig. 1a).
OspA from Bb strain B31, designated WT-OspA, and FTK-
OspA were expressed as GST-fusion proteins and were purified
by thrombin cleavage from the GST moiety. The resulting
recombinant protein preparations were of the anticipated mass
(28 kDa, data not shown).
Because the efficacy of OspA-derived vaccines is contingent
on a potent anti-OspA humoral response, it was critical to
demonstrate that the changes made in the T cell-reactive domain
of FTK-OspA did not significantly alter the protective antibody
response. We determined whether FTK-OspA was able to bind
a panel of OspA-specific mAbs by ELISA. mAbs specific for
either the OspA N terminus, H5332 (27), or the C terminus,
LA-2 (26), 9B3D (37), and CIII.78 (38) bound to both the
WT-OspA and mutated FTK-OspA in a similar fashion. No
reactivity to EV-Ctrl lysate was detected (Fig. 1b and data not
shown).
WT-OspA165–173-Specific T Cells Do Not Respond to FTK-OspA. We used
a panel of DR4-restricted murine THy and human T cell lines to
determine whether we had eliminated the DR4-restricted T cell
response to FTK-OspA by mutating the amino acids 165–173
epitope. THy were generated from OspA-immunized murine
MHC class II-deficient mice transgenic for chimeric mouse
MHC I-Ed with human DR4 - and -chains (23). DR4-
restricted THy specific for OspA165–173 produced significant
levels of IL-2 in response to WT-OspA in a dose-dependent
manner, but no IL-2 was detected in response to FTK-OspA or
to EV-Ctrl (Fig. 2a). To determine whether FTK-OspA could
Fig. 1. Mutant FTK-OspA, created by altering MHC-binding OspA epitope,
binds mAbs specific for WT-OspA. (a) Amino acid residues (165–173) that
contribute to the predicted DR4-binding score for Bb OspA (WT-OspA, from
Bb strains B31 or N40), FTK-OspA, B. afzelii OspA, and possible cross-reactive
human protein, LFA-1L (amino acids 332–340), are indicated. The amino acid
substitutions used in FTK-OspA (highlighted in gray) were designed to de-
crease the DR4-binding score of that epitope, as predicted by published
algorithms, but maintain a similar three-dimensional structure in the recom-
binant protein. (b) Serial dilutions of mAbs specific for two different WT-OspA
epitopes, H5332 (N terminus-specific, open and filled circles) and LA-2 (C
terminus-specific, open and filled squares) were added to WT-OspA and
FTK-OspA, and EV-Ctrl-coated wells in a direct-binding ELISA. Data are ex-
pressed as the OD405 value of one dilution of antibody. No antibody binding
to control lysate was detected.
Fig. 2. FTK-OspA does not stimulate OspA165–173-specific murine THy or
human T cell clones. (a) Two DR4-restricted THy (filled bars, DR4–38; diago-
nally hatched bars, DR4–51) were generated from mice with transgenic
human-mouse chimeric MHC class II molecules. THy specific for OspA165–173
were stimulated in quadruple with varied concentrations of WT-OspA, FTK-
OspA, or OspA peptides 164–183 or 234–253, plus DR4 APC. Secreted IL-2 was
measured by ELISA, and positive and negative controls were included on each
plate. Data are expressed as OD405. (b) L3C4, a DR1-restricted THy specific for
OspA234–253, was stimulated with OspA234–253, WT-OspA, FTK-OspA, EV-Ctrl, or
OspA165–173 presented by DR1 APCs. Secreted IL-2 was measured by ELISA. Data
are expressed as OD405. (c and d) Four human T cell clones were stimulated with
various concentrations of WT-OspA, FTK-OspA, or EV-Ctrl plus autologous LCL
APCs. (c) Proliferative response to antigen is measured as increase in
[3H]thymidine incorporation. Each bar (diagonally hatched, open, filled, or
crosshatched) represents a different T cell clone. The -cpm is calculated by
subtracting the mean media-stimulated cpm from the antigen-stimulated
cpm. (d) Antigen-stimulated IFN- secretion was measured by ELISA from
stimulated OspA-specific T cell clones from supernatants harvested at 48 h.
IFN- values were determined by comparing OD values with a standard curve.









stimulate L3C4, a DR1-restricted THy specific for an alternate
epitope of OspA, amino acids 234–253, THy cells were stimu-
lated with WT-OspA, FTK-OspA, or EV-Ctrl plus APC. L3C4
responded equally well to OspA234–253, WT-OspA, and FTK-
OspA, but not to OspA165–173 (Fig. 2b).
Additionally, we cultured WT-OspA165–173-specific human T
cell clones derived from a DR4-homozygous TRLA patient (33)
with WT-OspA, FTK-OspA, and EV-Ctrl. We reported (22) that
these OspA165–173-specific clones were cross-reactive with hLFA-
1L326–345. WT-OspA stimulated strong proliferation (Fig. 2c)
and induced secretion of high levels of IFN- (Fig. 2d), whereas
neither FTK-OspA nor EV-Ctrl was stimulatory (Fig. 2 c and d).
These results indicate that the FTK amino acid substitutions
were sufficient to abrogate the response of WT-OspA-specific,
DR4-restricted T cells to FTK-OspA.
OspA Antibody Response Results in Protection Against Bb Infection.
To determine the protective effect of immunization with
FTK-OspA, we characterized the anti-OspA antibodies pro-
duced in vitro and in vivo. We first determined the level of
anti-OspA antibodies produced in C3HHeJ mice vaccinated
with FTK-OspA or WT-OspA, or EV-Ctrl. Both WT- and
FTK-OspA induced equivalent levels of WT-OspA-specific
total IgG, IgG1, IgG2a, and IgG2b (Fig. 3). Negligible anti-
body responses were detected after vaccination with EV-Ctrl
(Fig. 3a).
Next, we measured the ability of serum from immunized mice
to competitively block binding of the WT-OspA-specific mAb,
LA-2, to OspA to determine the ‘‘LA-2 equivalency,’’ an in vitro
clinical correlate of a protective anti-OspA response (26). Serum
antibodies that can block binding of a known quantity of
biotin-labeled LA-2 mAb are quantitated by comparison with a
standard curve of unlabeled LA-2. We demonstrated that both
FTK- and WT-OspA-immunized mice produced similar levels of
LA-2-equivalent antibodies, whereas EV-Ctrl-immunized mice
produced background levels of LA-2-equivalent antibodies (Fig.
4a). These data indicate that immunization with FTK-OspA
elicits similar LA-2 equivalency and, therefore, protective anti-
body levels, as WT-OspA.
Finally, to prove the in vivo protective efficacy of the FTK-
OspA vaccine, C3HHeJ mice were immunized with FTK-
OspA, WT-OspA, or EV-Ctrl followed by intradermal challenge
with Bb strain N40. Protection from Bb challenge was deter-
mined by maximal ankle thickness after challenge (Fig. 4b).
Ankle thickness 300 m was considered positive ankle swell-
ing. The ability of FTK-OspA to protect mice from Bb infection
was similar to that of recombinant WT-OspA, with 86% and
75% of mice protected from ankle swelling, respectively (Table
Fig. 3. FTK-OspA stimulates anti-OspA serum antibody responses similar to
those stimulated by WT-OspA. C3HHeJ mice were immunized with FTK-OspA,
WT-OspA, adjuvant alone (mock), or EV-Ctrl in three doses. Sera were col-
lected 2 weeks after the final vaccine boost, and serial dilutions were assessed
for WT-OspA-specific antibodies by isotype-specific ELISA. Data are expressed
as OD405. (a) Total IgG. (b) IgG1. (c) IgG2a. (d) IgG2b. Data are combined from
two experiments.
Fig. 4. FTK-OspA immunization generates antibodies with protective ca-
pacities similar to WT-OspA. (a) C3H-HeJ mice were immunized with FTK-
OspA, WT-OspA, and EV-Ctrl as described, and the LA-2 equivalency (26) of
serum antibodies was assessed by means of competitive ELISA with labeled
LA-2 mAb. Data points indicate the LA-2 equivalency value of individual mice:
{, control; , WT-OspA; Œ, FTK-OspA. Data are combined from two indepen-
dent experiments. (b) FTK-OspA- and WT-OspA-vaccinated mice have reduced
ankle swelling after Bb challenge. C3HHeJ female mice were immunized with
FTK-OspA, WT-OspA, or EV-Ctrl. Mice were challenged 2 weeks after the third
vaccine dose by injection of Bb (EV-Ctrl, WT, and FTK) or BSK (mock) into the
right hind footpad. Ankle swelling was monitored for 3 weeks after challenge.
Each point represents the maximum ankle measurement recorded for each
mouse after challenge with Bb. Data include results from two independent
experiments.
Table 1. WT-OspA- and FTK-OspA-vaccinated C3HHeJ mice are protected against Bb infection
Group
Ankle swelling
total* Protection,† % Day of onset‡ (n) Bb outgrowth§ Bb† PCR¶
WT 416 75 14 (3), 17 (1) 27 416
FTK 216 86 14 (2) 06 216
EV-Ctrl 1111 0 11 (4), 12 (5), 14 (2) 66 1111
Mock 011 — — 05 06
*The number of mice showing ankle swelling of300 m over 3 weeks of observation over total mice per group;
C3HHeJ mice were vaccinated and challenged as described above.
†The percent of mice in each group that had no ankle swelling during 3 weeks of observation.
‡The day after infection that ankle swelling reached at least 300 m.
§The outgrowth of Bb from blood or bladder, expressed as number mice positive for Bb per total mice per group.
Mice with confirmed infection or positive PCR results correlated precisely with animals showing ankle swelling.
¶Genomic DNA from ear tissue was amplified with primers specific for Bb recA and scored on ethidium
bromide-stained agarose gels, expressed as number of mice with recA product per total mice per group.
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1). All mice immunized with EV-Ctrl developed ankle swelling
300 m. Meanwhile, none of the mock-infected (BSK medium
alone) mice developed ankle swelling (Fig. 4b and Table 1).
Protection from Bb infection was substantiated by culture of
spirochetes from blood or bladder tissue and by PCR for Bb
RecA DNA. Outgrowth of Bb from tissue samples was positively
correlated with ankle swelling data (Table 1). Similarly, PCR
products corresponding to the recA gene of Bb were generated
only from mice with ankle swelling (Table 1) and were not
present when no ankle swelling was observed. No Bb could be
cultured from mock-infected mice.
All strains of mice infected with Bb develop arthritis but with
marked variations in disease severity. Mice of the H-2k,b,j,r,s (e.g.,
C3HHen) haplotypes develop severe to moderate infection and
arthritis, whereas mice of the H-2d haplotype (BALBc) more
efficiently control Bb challenge and experience less severe
pathology (39). Previous vaccine studies (40) demonstrated that
WT-OspA could protect mice against infection with various Bb
strains. To demonstrate that FTK-OspA could elicit protective
immunity across different genetic backgrounds, BALBc mice
were vaccinated with FTK-OspA, adjuvant only, or were left
untreated before intradermal infection with low-passage B31, a
heterologous Bb strain (Fig. 5). Seven days after infection with
Bb, blood was drawn, diluted, and cultured for Bb outgrowth.
Whereas 75% of cultures from adjuvant (CFAIFA)-treated
and infection only control mice were positive for Bb growth,
none of the FTK-OspA-immunized mice were positive (Fig. 5a,
P  0.0001; Fisher’s exact test). Fourteen days after infection,
mice were killed and tissues were cultured for the presence of Bb.
There were no positive cultures from FTK-OspA-vaccinated
mice, compared with 75–100% Bb positive ear, heart, bladder, or
joint cultures from adjuvant only or infection only control mice
(Fig. 5b, P 0.0001; Fisher’s exact test). These data suggest that
FTK-OspA is as effective as WT-OspA in the prevention
of symptomatic Bb infection in mice of different genetic
backgrounds.
Discussion
In this report, we describe the generation of FTK-OspA, a
recombinant OspA molecule modified from Bb strain N40.
FTK-OspA retained its ability to induce protective antibody
responses, although lacking a potentially autoreactive T cell
epitope. The T cell domain of WT-OspA was modified by
substituting three residues from the N40 sequence with residues
contained in a nonarthritogenic Bb strain, B. afzelii (Fig. 1a).
These amino acid changes in the newly formed FTK-OspA
epitope resulted in a significant reduction in antigen presenta-
tion by the DR4 APC, as predicted by a published DR4-binding
algorithm (35). FTK-OspA did not stimulate epitope-specific,
potentially autoreactive human or mouse T cells in vitro, yet it
was as effective as WT-OspA in inducing protection against Bb
infection (Fig. 2).
The modification of a major T cell epitope in a vaccine agent
raises the concern that the necessary T cell help for humoral
immunity will be compromised. Although the C3HHeJ strain of
mice has been well established for testing the efficacy of Lyme
disease vaccine candidates, this strain cannot address this issue,
because the primary T cell epitope in the context of H-2k is
OspA179–193 (41). Thus, we used the class II-deficient, HLA-DR4
chimeric transgenic mice to determine whether OspA-specific
antibody titers were equivalent with FTK-OspA and WT-OspA
vaccination. Our findings that both total IgG and IgG1 subclass
titers were similar after WT- and FTK-OspA immunization
indicate that the T helper mediated class switching in these mice
does not depend on OspA165–173 presentation (Fig. 6, which is
published as supporting information on the PNAS web site). In
addition, our previous data indicate that the T cell response to
OspA165–173 is predominantly an inflammatory Th1 response
(21, 42). Thus, the FTK-OspA modification ablates a proinflam-
matory epitope in the context of DR4, while preserving struc-
tural integrity and remaining Th2 epitopes for the generation of
protective immunity.
We generated this modified rOspA vaccine in response to
concerns that the WT-OspA sequence used in previously devel-
oped vaccines contained an epitope that was cross-reactive with
a region of hLFA-1L. Vaccination of individuals who possess
rheumatoid arthritis-associated MHC class II alleles, such as
DR4, could potentially elicit autoreactive T cells after WT-OspA
exposure. Because LFA-1L is up-regulated at sites of inflam-
mation, this self-antigen would be readily available to stimulate
OspA-primed T cells at various sites in the body, including the
vaccination site. Individuals in the clinical vaccine trial reported
an increased incidence of localized pain after vaccine adminis-
tration versus placebo administration; however, this reaction
subsided in most recipients within 30 days (13). Further, the
broad expression pattern of LFA-1L could lead to a variety of
adverse reactions that are not limited to arthritis.
Several studies have demonstrated an association between
immunity to OspA and crossreactivity to hLFA-1L in individ-
uals of a select MHC background (22, 43, 44). In one report, the
data did not support a link between reactivity to hLFA-1L and
clinical status (arthritis); unfortunately, the patient genetic back-
grounds were not determined (45). However, in another study,
arthritis was reported after vaccination in four males: two adults,
and two children (46). By using data compiled from the Vaccine
Adverse Events Reporting System database (Food and Drug
Administration and Centers for Disease Control and Preven-
tion) to identify any unusual patterns of adverse events in
OspA-vaccinated individuals, one report indicated a possible
link between the DR4 allele and individuals suffering from
serious Lyme vaccine-related illnesses (47). This connection may
be confounded by bias in self-reporting. In an interesting devel-
opment, the LYMErix vaccine has been removed from the
market.
The incidence of Lyme disease in the United States remains
high and this fact underlines the need for additional pharma-
ceutical approaches to controlling infection. OspA vaccines used
in humans have demonstrated a 76% efficacy and function by
inducing anti-OspA antibodies that block the transmission of Bb
from the tick to the mammalian host. However, if Bb escape
Fig. 5. FTK-OspA vaccination abolishes outgrowth of Bb in BALBc mice.
After vaccination with FTK-OspA (n  15), adjuvant (CFAIFA, n  10), or no
treatment (infection only, n 10), BALBc mice were challenged with Bb B31.
(a) At day 14 postinfection, blood was harvested and diluted 1:100 (filled bar)
or 1:1,000 (open bar) and cultured in BSK medium to detect the outgrowth of
Bb. (b) Joint (diagonal crosshatched bar), bladder (filled bar), heart (vertical
crosshatched bar), and ear tissue (open bar) were harvested and cultured in
BSK to detect the outgrowth of Bb. Data are expressed as percent positive
Borrelia cultures for each pretreatment group. *, P 0.0001 by Fisher’s exact
test.









killing in the tick and are successfully transferred to the human
host, they may escape elimination in the host because Bb
down-regulate OspA expression as they make their way from the
tick midgut to the salivary gland and into the host (48, 49). To
avoid immune evasion in the host, an effective approach is to
design a multivalent vaccine. Decorin-binding protein A, in
combination with OspA, has been shown to confer a synergistic
enhancement of protection against Bb infection (50). Addition-
ally, developing a OspA-based combination vaccination with
decorin-binding protein A may allow for an anamnestic response
in the event of infection, because decorin-binding protein A is
significantly up-regulated in the mammalian host (51). Other Bb
proteins examined for vaccine efficacy include OspC (52),
p35Bbk32 (53), and VraABB116 (54). Multivalent vaccines
may also result in increased protection against heterologous Bb
strains (55), because crossprotection with unmodified OspA
proteins has been difficult to achieve due to Bb heterogeneity
(56). These combined data suggest that an optimal second
generation Lyme disease vaccine could consist of FTK-OspA
and one or two other vaccine candidates.
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